Astellas Pharma Inc., of Tokyo, and the Dana-Farber Cancer Institute inked a three-year agreement to research and develop small-molecule inhibitors of oncogenic KRAS for the treatment of cancer, including lung cancer. Read More
Ruthigen Inc., of Santa Rosa, Calif., said it enrolled the first patient in a phase I/II trial of RUT58-60, its broad-spectrum anti-infective, for use as an adjunct to systemic antibiotics in abdominal surgery. Read More
Catalyst Pharmaceutical Partners Inc., of Coral Gables, Fla., said it entered a memorandum of understanding with lead plaintiffs to settle its pending class-action securities lawsuit regarding the development of Firdapse (amifampridine phosphate). Read More
Regulus Therapeutics Inc., of La Jolla, Calif., closed its previously announced underwritten public offering of $103.5 million of shares of its common stock, including $13.5 million of shares sold pursuant to the full exercise of the underwriters' option to purchase additional shares, at a price to the public of $17 per share. Read More
The FDA briefing documents for Thursday's Oncologic Drugs Advisory Committee (ODAC) meeting sent Rockwell Medical Inc.'s (NASDAQ:RMTI) stock up 21.5 percent Tuesday, to close at $10.63. Read More
BOGOTA, Colombia – As it works to cut costs in the provision of health care, the government of Colombia is more aggressively enforcing price caps for drugs, and in particular, more expensive biologics. Read More
HONG KONG – This year has been a good one for biopharma companies in China, many of which are combining a growing market with stronger R&D pipelines, some government support and more tightly controlled expenses and are turning out some positive results. Read More
LONDON – Damping down a type of low-grade inflammation that occurs in adipose tissue – particularly in those who are obese – could be a way to control type 2 diabetes and obesity in the future, scientists said. Read More
FRANKFURT – Big pharma's and big biotech's rapid push into cancer immunotherapy has become a major theme in the business – as well as the drug – development strategies of the main players, all of which are vying to gain an edge on their rivals. Read More
Following up a whopper deal with Biogen Idec Inc. about a year ago, Proteostasis Therapeutics Inc. (PTI) nailed down a pact with Astellas Pharma Inc. that brings up-front cash, a securities investment and potentially $400 million in milestone payments, ultimately gaining as much as $1.2 billion if Astellas exercises options for two more projects under the same terms and they succeed fully. Read More
Despite a 48 percent increase in third quarter global sales of Eylea (aflibercept) compared to the same period a year earlier, to $722 million, including 23 percent growth in U.S. sales, shares of Regeneron Pharmaceuticals Inc. (NASDAQ:REGN)dipped 5.8 percent Tuesday as investors fretted over more conservative estimates for full-year sales. Read More
